Avoidant/Restrictive Food Intake Disorder (ARFID): Symptoms, Causes, Diagnosis, and Treatment

Avoidant/Restrictive Food Intake Disorder (ARFID) is a feeding and eating disorder characterized by a persistent failure to meet appropriate nutritional and/or energy needs. Unlike anorexia nervosa or bulimia nervosa, ARFID does not involve distress about body shape or weight, nor a desire to be thinner. Instead, individuals with ARFID avoid or restrict food intake due to sensory sensitivities, fear of aversive consequences (such as choking or vomiting), or an apparent lack of interest in eating.

ARFID was introduced as a formal diagnosis in the DSM-5 (2013), replacing and expanding the earlier childhood diagnosis of "Feeding Disorder of Infancy or Early Childhood." This reclassification was significant because it recognized that restrictive eating patterns causing clinical impairment can occur at any age — not just in young children. The DSM-5-TR retains this diagnostic framework and emphasizes that ARFID is a heterogeneous condition with multiple potential presentations.

It is important to distinguish ARFID from typical picky eating, which is common in childhood and usually resolves without lasting nutritional or psychosocial consequences. In ARFID, the avoidance or restriction is severe enough to result in significant weight loss, nutritional deficiency, dependence on oral supplements or enteral feeding, or marked interference with psychosocial functioning — such as being unable to eat with others or participate in social events involving food.

Prevalence estimates for ARFID vary depending on the population studied and the methods used, but the condition is increasingly recognized as more common than previously thought. In pediatric eating disorder treatment settings, ARFID accounts for an estimated 5% to 23% of cases, making it a substantial subset of presentations. In the general population, research suggests prevalence rates ranging from approximately 0.5% to 5%, though methodological differences across studies contribute to this wide range.

ARFID appears to be more common in children and adolescents than in adults, though adult-onset and adult-persistent cases are well documented. Unlike anorexia nervosa and bulimia nervosa, which disproportionately affect females, ARFID shows a more balanced gender distribution, with some studies suggesting a slight male predominance, particularly in younger samples.

The condition is also significantly more prevalent among individuals with autism spectrum disorder (ASD), attention-deficit/hyperactivity disorder (ADHD), anxiety disorders, and intellectual disabilities. These high-comorbidity populations are an area of active research, and clinicians working with neurodivergent individuals are increasingly screening for ARFID presentations.

ARFID presentations typically fall into three overlapping profiles, though many individuals show features of more than one:

• Sensory sensitivity: The individual avoids foods based on their texture, taste, smell, appearance, or temperature. They may describe certain foods as intolerable or disgusting in ways that go far beyond ordinary preferences. This is sometimes called "selective eating" and is the most common presentation, particularly in children.
• Fear of aversive consequences: The individual avoids eating due to a specific fear, such as choking, vomiting, gagging, allergic reactions, or abdominal pain. This presentation often develops after a frightening experience with food (a choking episode, for example) and can lead to progressive restriction of the diet.
• Low interest in eating or food (apparent lack of appetite): The individual shows little drive to eat, reports forgetting meals, feeling full quickly, or finding eating to be a chore rather than pleasurable. This presentation may be associated with interoceptive differences — difficulty recognizing internal hunger signals.

Regardless of the specific profile, warning signs that food avoidance has reached clinical significance include:

• Significant weight loss or, in children, failure to achieve expected weight gain or growth
• Nutritional deficiencies (such as iron-deficiency anemia, vitamin D deficiency, zinc deficiency, or scurvy from inadequate vitamin C)
• Dependence on nutritional supplements, meal replacement shakes, or tube feeding to maintain adequate nutrition
• Marked psychosocial impairment: avoiding social situations involving food, conflict at mealtimes, inability to eat at restaurants or at others' homes, distress when faced with unfamiliar foods
• An extremely limited diet — sometimes fewer than 10–20 accepted foods — that may narrow further over time
• Fatigue, dizziness, hair loss, feeling cold, or other signs of malnutrition

Parents and caregivers should be alert to patterns where a child's food repertoire is shrinking rather than expanding with age, or where mealtimes consistently involve extreme distress.

ARFID does not have a single cause. Like most eating disorders, it arises from a complex interaction of biological, psychological, and environmental factors. Current research points to several key contributors:

Biological and Neurobiological Factors

• Sensory processing differences: Many individuals with ARFID have heightened sensitivity to sensory input — not just with food, but across domains. They may also be sensitive to clothing textures, sounds, or visual stimuli. Research suggests these sensory sensitivities have a neurobiological basis and are often present from early development.
• Interoception difficulties: Some individuals have reduced awareness of hunger and satiety cues, which may be linked to differences in the interoceptive system — the brain's ability to sense and interpret internal body signals.
• Genetic predisposition: Emerging research suggests a heritable component to ARFID, particularly overlapping with genetic factors for anxiety, neurodevelopmental conditions, and other eating disorders. Twin and family studies in this area are still in early stages.
• Gastrointestinal conditions: Chronic gastrointestinal symptoms — such as gastroesophageal reflux disease (GERD), eosinophilic esophagitis, food allergies, or irritable bowel syndrome — can contribute to learned food avoidance, especially when eating is repeatedly associated with pain or discomfort.

Psychological Factors

• Anxiety and anxiety disorders: Anxiety is one of the strongest correlates of ARFID. Generalized anxiety, specific phobias, and obsessive-compulsive tendencies are frequently comorbid. The fear-based presentation of ARFID shares mechanisms with phobic disorders.
• Neurodevelopmental conditions: Autism spectrum disorder and ADHD are both associated with elevated rates of ARFID. In ASD, rigid thinking patterns, sensory hypersensitivity, and insistence on sameness may all contribute. In ADHD, difficulty with appetite regulation (sometimes exacerbated by stimulant medication) and executive functioning challenges may play a role.
• Traumatic food-related experiences: A choking incident, a severe episode of food poisoning, forceful feeding during childhood, or witnessing someone else's aversive food experience can trigger the onset of ARFID, particularly the fear-based subtype.

Environmental and Social Factors

• Early feeding experiences: Difficulties with breastfeeding, premature birth, prolonged tube feeding in infancy, or early medical interventions involving the mouth and throat can disrupt the typical development of eating skills and comfort with oral intake.
• Family mealtime dynamics: High-pressure feeding environments — where children are forced to eat, punished for food refusal, or subjected to chronic mealtime conflict — can inadvertently reinforce avoidance behaviors.
• Limited food exposure: Children who are not introduced to a variety of tastes and textures during the critical window of complementary feeding (roughly 6–18 months) may have increased difficulty accepting new foods later.

ARFID is diagnosed according to the criteria outlined in the DSM-5-TR (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision). The diagnosis requires the following:

Criterion A: An eating or feeding disturbance (such as apparent lack of interest in eating or food, avoidance based on sensory characteristics, or concern about aversive consequences of eating) as manifested by persistent failure to meet appropriate nutritional and/or energy needs, associated with one or more of the following:

• Significant weight loss (or failure to achieve expected weight gain or growth in children)
• Significant nutritional deficiency
• Dependence on enteral feeding or oral nutritional supplements
• Marked interference with psychosocial functioning

Criterion B: The disturbance is not better explained by lack of available food or by an associated culturally sanctioned practice (such as religious fasting).

Criterion C: The eating disturbance does not occur exclusively during the course of anorexia nervosa or bulimia nervosa, and there is no evidence of disturbance in the way one's body weight or shape is experienced.

Criterion D: The eating disturbance is not attributable to a concurrent medical condition or not better explained by another mental disorder. When the eating disturbance occurs in the context of another condition, it must be sufficiently severe to warrant additional clinical attention.

The Diagnostic Process

A thorough ARFID assessment typically involves multiple components:

• Clinical interview: A detailed history of eating behaviors, food preferences, onset and trajectory of avoidance, any precipitating events, and the individual's subjective experience of eating. The clinician will explore all three ARFID presentations.
• Medical evaluation: Physical examination, growth chart review (in children and adolescents), and laboratory tests to assess for nutritional deficiencies (complete blood count, iron studies, vitamin levels, metabolic panel, thyroid function). Gastrointestinal evaluation may be warranted to rule out or identify co-occurring medical conditions.
• Nutritional assessment: A registered dietitian may conduct a detailed food diary analysis, assess caloric and nutrient adequacy, and map the range of accepted foods.
• Screening tools: The Nine Item ARFID Screen (NIAS) and the Pica, ARFID, and Rumination Disorder Interview (PARDI) are validated instruments used to aid in identification and characterization of ARFID. The PARDI, in particular, assesses all three motivational profiles and their severity.
• Psychosocial assessment: Evaluation of comorbid conditions (anxiety, ASD, ADHD, depression), psychosocial functioning, family dynamics, and the impact of restrictive eating on daily life.

Differential diagnosis is an important part of the evaluation. Clinicians must carefully distinguish ARFID from anorexia nervosa, other specified feeding or eating disorder (OSFED), medical conditions that suppress appetite (such as inflammatory bowel disease or malignancy), and normative developmental picky eating.

Treatment for ARFID is multimodal and is typically tailored to the individual's specific presentation (sensory sensitivity, fear-based, or low appetite), age, severity of nutritional compromise, and co-occurring conditions. While research on ARFID-specific treatments is growing rapidly, it remains an area where the evidence base is less established than for anorexia nervosa or bulimia nervosa. The following approaches have the strongest support to date:

Cognitive-Behavioral Therapy for ARFID (CBT-AR)

Developed by Dr. Jennifer Thomas and colleagues at Massachusetts General Hospital, CBT-AR is currently the most rigorously studied psychotherapy for ARFID. It is a structured, typically 20–30 session outpatient treatment that addresses all three ARFID presentations through four stages:

• Stage 1 — Psychoeducation and early change: Building a formulation of the individual's ARFID, introducing regular eating patterns, and addressing any acute nutritional needs.
• Stage 2 — Sensory sensitivity module: Systematic, gradual food exposure using a hierarchy — starting with foods similar to accepted ones and progressively introducing novel textures, tastes, and types.
• Stage 3 — Fear-based module: Using cognitive restructuring and interoceptive exposure techniques (similar to those used in panic disorder treatment) to address fears of choking, vomiting, or other aversive consequences.
• Stage 4 — Relapse prevention: Consolidating gains, planning for high-risk situations, and establishing ongoing food exploration practices.

Early clinical trials and case series show promising results, with significant increases in dietary variety, weight restoration, and reduction in ARFID severity scores.

Family-Based Treatment (FBT) Adapted for ARFID

For children and younger adolescents, adaptations of Family-Based Treatment (Maudsley approach) have been developed. In this model, parents take an active role in supporting nutritional rehabilitation and gradual food exposure. The adapted approach is less focused on weight restoration alone and more focused on expanding the range of accepted foods and reducing mealtime distress. Preliminary research supports its feasibility and effectiveness, particularly for younger patients.

Exposure-Based Therapies

For fear-based ARFID presentations, graded exposure therapy — in which the individual is systematically and progressively exposed to feared foods or eating situations — is a core treatment component. This may involve hierarchical food chaining (moving from accepted foods to similar but novel foods), in-session eating exercises, and interoceptive exposures targeting feared bodily sensations.

Nutritional Rehabilitation and Medical Management

Regardless of the psychotherapeutic approach, nutritional rehabilitation is a critical component of ARFID treatment. This may involve:

• Working with a registered dietitian to optimize caloric and nutrient intake within the individual's current accepted foods
• Strategic use of oral nutritional supplements or fortified foods to address deficiencies
• In severe cases, nasogastric tube feeding or hospitalization may be necessary to stabilize medical status before psychotherapy can be effectively initiated
• Correction of specific deficiencies (iron, zinc, B vitamins, vitamin D) through supplementation

Pharmacotherapy

There are currently no medications approved specifically for ARFID. However, medications may play a supportive role in certain cases:

• Anxiolytics or SSRIs may be considered when significant comorbid anxiety is identified, particularly in fear-based presentations
• Cyproheptadine, an antihistamine with appetite-stimulating properties, has been used off-label in some pediatric cases to increase appetite, though evidence is limited
• Olanzapine has been explored in small studies for its appetite-stimulating effects, but is not considered standard practice for ARFID
• Medication for comorbid conditions (e.g., ADHD, depression) should be carefully managed, as some medications can affect appetite

Occupational Therapy and Feeding Therapy

For individuals — particularly young children — whose ARFID is related to oral-motor difficulties or severe sensory processing challenges, occupational therapy and specialized feeding therapy (such as the SOS Approach to Feeding) can be valuable. These approaches work on desensitization to food textures, building oral-motor skills, and creating positive associations with mealtime.

The prognosis for ARFID is variable and depends on several factors, including the specific presentation, age of onset, severity and duration of the condition, the presence of comorbid conditions, and access to appropriate treatment.

Favorable prognostic factors include:

• Earlier identification and intervention
• A clear precipitating event (such as a choking episode) where fear-based avoidance has not generalized extensively
• Absence of severe comorbid conditions
• A supportive family and treatment environment
• Willingness to engage with exposure-based work

Factors associated with a more protracted course include:

• Co-occurring autism spectrum disorder, which may make sensory-based food avoidance more entrenched and less responsive to standard exposure approaches
• Multiple overlapping ARFID presentations (e.g., both sensory sensitivity and low appetite)
• Long duration of illness with deeply established avoidance patterns
• Significant medical complications or severe malnutrition at the time of diagnosis
• Comorbid anxiety disorders that are untreated

It is important to set realistic expectations for recovery. For many individuals, particularly those with the sensory sensitivity presentation, treatment goals may focus on expanding the diet to a degree that supports adequate nutrition and improved social functioning, rather than achieving a completely unrestricted relationship with food. Some degree of food selectivity may persist lifelong but can be managed effectively.

Research on long-term outcomes is still limited. Some longitudinal studies in pediatric populations suggest that a subset of children with ARFID-like presentations in early childhood do show improvement over time, particularly with appropriate intervention. However, untreated ARFID can persist into adulthood and lead to chronic health consequences, including osteoporosis, growth failure, dental erosion, compromised immune function, and psychosocial isolation.

Recovery is often nonlinear. Periods of progress may alternate with setbacks, particularly during transitions (starting school, moving, changes in routine) or times of increased stress or illness. Ongoing support and a long-term perspective are essential.

ARFID frequently co-occurs with and must be differentiated from several other conditions:

• Autism Spectrum Disorder (ASD): Restricted eating is extremely common in ASD, with estimates suggesting that 50–70% of autistic children exhibit significant feeding difficulties. ARFID can be diagnosed alongside ASD when the eating disturbance warrants additional clinical attention beyond what is typical for the neurodevelopmental condition.
• Anxiety Disorders: Generalized anxiety disorder, social anxiety disorder, and specific phobias co-occur with ARFID at high rates. The fear-based presentation of ARFID shares underlying mechanisms with phobic anxiety, and elevated trait anxiety is common across all presentations.
• Attention-Deficit/Hyperactivity Disorder (ADHD): ADHD is associated with irregular eating patterns, appetite dysregulation, and difficulty with the executive functioning demands of meal planning and preparation. Stimulant medications used to treat ADHD can further suppress appetite.
• Obsessive-Compulsive Disorder (OCD): Rigidity around food, ritualistic eating behaviors, and contamination-related food avoidance can overlap with both OCD and ARFID. Careful diagnostic assessment is needed to determine whether food avoidance is driven by obsessive-compulsive mechanisms, ARFID-related sensory or fear concerns, or both.
• Anorexia Nervosa: The primary differentiating factor is motivation — anorexia nervosa involves body image disturbance and fear of weight gain, while ARFID does not. However, some individuals may present with overlapping features, and diagnostic presentations can evolve over time.
• Functional Gastrointestinal Disorders: Conditions such as irritable bowel syndrome (IBS), functional dyspepsia, and functional nausea commonly co-occur with ARFID and can both cause and maintain food avoidance behaviors.
• Depression: Depressive disorders can contribute to appetite loss and disinterest in eating, overlapping with the low-appetite presentation of ARFID. When depression is effectively treated and eating normalizes, a separate ARFID diagnosis may not be warranted.

It can be challenging to determine when selective or limited eating crosses the line from a preference into a clinical concern. The following signs suggest that professional evaluation for ARFID is appropriate:

• Weight loss, failure to gain weight, or falling off a growth curve (in children and adolescents)
• The range of accepted foods is very narrow (often fewer than 20 foods) and continuing to shrink rather than expand
• Nutritional deficiencies have been identified, or there are physical symptoms of malnutrition (fatigue, hair loss, brittle nails, frequent illness, dizziness)
• The individual relies on nutritional supplements or a very limited number of foods to meet basic caloric needs
• Mealtimes are consistently a source of significant distress, conflict, or anxiety for the individual or the family
• Eating difficulties are impairing social functioning: avoiding eating in public, declining invitations to meals or events, or experiencing shame or isolation related to eating
• A traumatic food-related event (choking, vomiting, allergic reaction) has led to progressive food avoidance
• The individual expresses fear or anxiety about eating specific foods or eating in general, but does not express concerns about weight or body shape

The first step is often a visit with a primary care physician or pediatrician, who can assess growth, order relevant laboratory tests, and provide referrals. From there, evaluation by a psychologist or psychiatrist experienced with eating disorders — ideally one familiar with ARFID specifically — is recommended. A registered dietitian with expertise in eating disorders should also be part of the treatment team.

For children, early intervention is strongly associated with better outcomes. If your child's pediatrician dismisses selective eating concerns as something the child will "grow out of" but you are observing nutritional compromise, psychosocial impairment, or escalating distress, seeking a second opinion from an eating disorder specialist is advisable.

In cases of severe malnutrition, rapid weight loss, or medical instability, seek immediate medical attention. ARFID can cause serious medical complications when nutritional intake is severely compromised, and medical stabilization may be needed before outpatient psychotherapy can begin.